Tag: Trial

Japanese drugmaker Eisai & Co and Chinese drug developer Bliss Biopharmaceutical (Hangzhou) Co., have entered into a joint development agreement to further develop BB-1701, an antibody-drug conjugate (ADC). As part of the agreement Eisai & Co obtained option rights for a strategic collaboration.

To-date, the treatment of acute myeloid leukemia or  AML remains general unsatisfactory.  Both the medical and scientific communities are looking for urgently needed novel...

Data presented at the 2014 Annual Bone Marrow Transplant (BMT) Tandem Meetings organized by The American Society for Blood and Marrow Transplantation and the Center for International Blood & Marrow Transplant Research being held in Grapevine (Dallas), Texas, February 26 - March 2, 2014, highlights the benefits of brentuximab vedotin (Adcetris®; Seattle Genetics) in various treatment schedules for hard to treat cancers.

In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported...

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38% of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in...